July 17, 2018
Taiho Pharmaceutical said on July 13 that it has acquired exclusive development and commercialization rights to Arcus Biosciences’ immuno-oncology candidate AB928 and its backup compounds in Japan and certain other Asian territories excluding China. The Japanese company obtained the rights...read more